| MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1*♦ TE Miller, K Ghoshal, B Ramaswamy, S Roy, J Datta, CL Shapiro, S Jacob, ... Journal of biological chemistry 283 (44), 29897-29903, 2008 | 934 | 2008 |
| Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway B Ramaswamy, Y Lu, K Teng, G Nuovo, X Li, CL Shapiro, S Majumder Cancer research 72 (19), 5048-5059, 2012 | 225 | 2012 |
| Osteopenia and osteoporosis in women with breast cancer B Ramaswamy, CL Shapiro Seminars in oncology 30 (6), 763-775, 2003 | 182 | 2003 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 163 | 2022 |
| Randomized phase II Trial of Fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative … N Kornblum, F Zhao, J Manola, P Klein, B Ramaswamy, A Brufsky, ... Journal of Clinical Oncology 36 (16), 1556, 2018 | 154 | 2018 |
| Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients B Ramaswamy, AD Elias, NT Kelbick, A Dodley, M Morrow, M Hauger, ... Clinical cancer research 12 (10), 3124-3129, 2006 | 145 | 2006 |
| Giant breast tumors: surgical management of phyllodes tumors, potential for reconstructive surgery and a review of literature MI Liang, B Ramaswamy, CC Patterson, MT McKelvey, G Gordillo, ... World Journal of Surgical Oncology 6, 1-8, 2008 | 141 | 2008 |
| Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients MB Lustberg, P Balasubramanian, B Miller, A Garcia-Villa, C Deighan, ... Breast Cancer Research 16, 1-15, 2014 | 122 | 2014 |
| Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation DK Ahirwar, MW Nasser, MM Ouseph, M Elbaz, MC Cuitiño, RD Kladney, ... Oncogene 37 (32), 4428-4442, 2018 | 115 | 2018 |
| Anti-microRNA-222 (anti-miR-222) and-181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal Y Lu, S Roy, G Nuovo, B Ramaswamy, T Miller, C Shapiro, ST Jacob, ... Journal of Biological Chemistry 286 (49), 42292-42302, 2011 | 114 | 2011 |
| The Hedgehog signaling pathway: a viable target in breast cancer? P Bhateja, M Cherian, S Majumder, B Ramaswamy Cancers 11 (8), 1126, 2019 | 110 | 2019 |
| Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients SM Monfort, X Pan, R Patrick, B Ramaswamy, R Wesolowski, ... Breast cancer research and treatment 164, 69-77, 2017 | 110 | 2017 |
| Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ... Journal of Clinical Oncology 39 (21), 2375-2385, 2021 | 106 | 2021 |
| Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer M Zhao, B Ramaswamy World journal of clinical oncology 5 (3), 248, 2014 | 93 | 2014 |
| Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo B Ramaswamy, W Fiskus, B Cohen, C Pellegrino, DL Hershman, ... Breast cancer research and treatment 132, 1063-1072, 2012 | 91 | 2012 |
| Gene expression profiling: changing face of breast cancer classification and management R Wesolowski, B Ramaswamy Gene expression 15 (3), 105, 2011 | 79 | 2011 |
| Estrogen receptor beta (ERβ): a ligand activated tumor suppressor R Mal, A Magner, J David, J Datta, M Vallabhaneni, M Kassem, ... Frontiers in Oncology 10, 587386, 2020 | 78 | 2020 |
| PD‐L1 expression and CD8‐positive T cells are associated with favorable survival in HER2‐positive invasive breast cancer Y Hou, H Nitta, L Wei, PM Banks, M Lustberg, R Wesolowski, ... The breast journal 24 (6), 911-919, 2018 | 77 | 2018 |
| Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer T Zuo, TM Liu, X Lan, YI Weng, R Shen, F Gu, YW Huang, ... Cancer research 71 (5), 1752-1762, 2011 | 71 | 2011 |
| Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer R Wesolowski, MC Duggan, A Stiff, J Markowitz, P Trikha, KM Levine, ... Cancer Immunology, Immunotherapy 66, 1437-1447, 2017 | 70 | 2017 |
